Transiently lowering tumor necrosis factor-aα synthesis ameliorates neuronal cell loss and cognitive impairments induced by minimal traumatic brain injury in mice

Renana Baratz, David Tweedie, Jia Yi Wang, Vardit Rubovitch, Weiming Luo, Barry J. Hoffer, Nigel H. Greig, Chaim G. Pick

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Background: The treatment of traumatic brain injury (TBI) represents an unmet medical need, as no effective pharmacological treatment currently exists. The development of such a treatment requires a fundamental understanding of the pathophysiological mechanisms that underpin the sequelae resulting from TBI, particularly the ensuing neuronal cell death and cognitive impairments. Tumor necrosis factor-alpha (TNF-aα) is a cytokine that is a master regulator of systemic and neuroinflammatory processes. TNF-aα levels are reported to become rapidly elevated post TBI and, potentially, can lead to secondary neuronal damage. Methods: To elucidate the role of TNF-aα in TBI, particularly as a drug target, the present study evaluated (i) time-dependent TNF-aα levels and (ii) markers of apoptosis and gliosis within the brain and related these to behavioral measures of 'well being' and cognition in a mouse closed head 50 g weight drop mild TBI (mTBI) model in the presence and absence of post-treatment with an experimental TNF-aα synthesis inhibitor, 3,6'-dithiothalidomide. Results: mTBI elevated brain TNF-aα levels, which peaked at 12 h post injury and returned to baseline by 18 h. This was accompanied by a neuronal loss and an increase in astrocyte number (evaluated by neuronal nuclei (NeuN) and glial fibrillary acidic protein (GFAP) immunostaining), as well as an elevation in the apoptotic death marker BH3-interacting domain death agonist (BID) at 72 h. Selective impairments in measures of cognition, evaluated by novel object recognition and passive avoidance paradigms - without changes in well being, were evident at 7 days after injury. A single systemic treatment with the TNF-aα synthesis inhibitor 3,6'-dithiothalidomide 1 h post injury prevented the mTBI-induced TNF-aα elevation and fully ameliorated the neuronal loss (NeuN), elevations in astrocyte number (GFAP) and BID, and cognitive impairments. Cognitive impairments evident at 7 days after injury were prevented by treatment as late as 12 h post mTBI but were not reversed when treatment was delayed until 18 h. Conclusions: These results implicate that TNF-aα in mTBI induced secondary brain damage and indicate that pharmacologically limiting the generation of TNF-aα post mTBI may mitigate such damage, defining a time-dependent window of up to 12 h to achieve this reversal.

Original languageEnglish
Article number45
JournalJournal of Neuroinflammation
Volume12
Issue number1
DOIs
Publication statusPublished - Mar 7 2015

Fingerprint

Tumor Necrosis Factor-alpha
Glial Fibrillary Acidic Protein
Wounds and Injuries
Astrocytes
Cognition
Brain Concussion
Cognitive Dysfunction
Traumatic Brain Injury
Gliosis
Brain
Brain Neoplasms
Cell Death
Head
Pharmacology
Apoptosis
Cytokines
Weights and Measures
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Neuroscience(all)
  • Cellular and Molecular Neuroscience
  • Neurology
  • Immunology

Cite this

Transiently lowering tumor necrosis factor-aα synthesis ameliorates neuronal cell loss and cognitive impairments induced by minimal traumatic brain injury in mice. / Baratz, Renana; Tweedie, David; Wang, Jia Yi; Rubovitch, Vardit; Luo, Weiming; Hoffer, Barry J.; Greig, Nigel H.; Pick, Chaim G.

In: Journal of Neuroinflammation, Vol. 12, No. 1, 45, 07.03.2015.

Research output: Contribution to journalArticle

Baratz, Renana ; Tweedie, David ; Wang, Jia Yi ; Rubovitch, Vardit ; Luo, Weiming ; Hoffer, Barry J. ; Greig, Nigel H. ; Pick, Chaim G. / Transiently lowering tumor necrosis factor-aα synthesis ameliorates neuronal cell loss and cognitive impairments induced by minimal traumatic brain injury in mice. In: Journal of Neuroinflammation. 2015 ; Vol. 12, No. 1.
@article{b6c7d80b56224c36aa02969f1c210c2b,
title = "Transiently lowering tumor necrosis factor-aα synthesis ameliorates neuronal cell loss and cognitive impairments induced by minimal traumatic brain injury in mice",
abstract = "Background: The treatment of traumatic brain injury (TBI) represents an unmet medical need, as no effective pharmacological treatment currently exists. The development of such a treatment requires a fundamental understanding of the pathophysiological mechanisms that underpin the sequelae resulting from TBI, particularly the ensuing neuronal cell death and cognitive impairments. Tumor necrosis factor-alpha (TNF-aα) is a cytokine that is a master regulator of systemic and neuroinflammatory processes. TNF-aα levels are reported to become rapidly elevated post TBI and, potentially, can lead to secondary neuronal damage. Methods: To elucidate the role of TNF-aα in TBI, particularly as a drug target, the present study evaluated (i) time-dependent TNF-aα levels and (ii) markers of apoptosis and gliosis within the brain and related these to behavioral measures of 'well being' and cognition in a mouse closed head 50 g weight drop mild TBI (mTBI) model in the presence and absence of post-treatment with an experimental TNF-aα synthesis inhibitor, 3,6'-dithiothalidomide. Results: mTBI elevated brain TNF-aα levels, which peaked at 12 h post injury and returned to baseline by 18 h. This was accompanied by a neuronal loss and an increase in astrocyte number (evaluated by neuronal nuclei (NeuN) and glial fibrillary acidic protein (GFAP) immunostaining), as well as an elevation in the apoptotic death marker BH3-interacting domain death agonist (BID) at 72 h. Selective impairments in measures of cognition, evaluated by novel object recognition and passive avoidance paradigms - without changes in well being, were evident at 7 days after injury. A single systemic treatment with the TNF-aα synthesis inhibitor 3,6'-dithiothalidomide 1 h post injury prevented the mTBI-induced TNF-aα elevation and fully ameliorated the neuronal loss (NeuN), elevations in astrocyte number (GFAP) and BID, and cognitive impairments. Cognitive impairments evident at 7 days after injury were prevented by treatment as late as 12 h post mTBI but were not reversed when treatment was delayed until 18 h. Conclusions: These results implicate that TNF-aα in mTBI induced secondary brain damage and indicate that pharmacologically limiting the generation of TNF-aα post mTBI may mitigate such damage, defining a time-dependent window of up to 12 h to achieve this reversal.",
author = "Renana Baratz and David Tweedie and Wang, {Jia Yi} and Vardit Rubovitch and Weiming Luo and Hoffer, {Barry J.} and Greig, {Nigel H.} and Pick, {Chaim G.}",
year = "2015",
month = "3",
day = "7",
doi = "10.1186/s12974-015-0237-4",
language = "English",
volume = "12",
journal = "Journal of Neuroinflammation",
issn = "1742-2094",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Transiently lowering tumor necrosis factor-aα synthesis ameliorates neuronal cell loss and cognitive impairments induced by minimal traumatic brain injury in mice

AU - Baratz, Renana

AU - Tweedie, David

AU - Wang, Jia Yi

AU - Rubovitch, Vardit

AU - Luo, Weiming

AU - Hoffer, Barry J.

AU - Greig, Nigel H.

AU - Pick, Chaim G.

PY - 2015/3/7

Y1 - 2015/3/7

N2 - Background: The treatment of traumatic brain injury (TBI) represents an unmet medical need, as no effective pharmacological treatment currently exists. The development of such a treatment requires a fundamental understanding of the pathophysiological mechanisms that underpin the sequelae resulting from TBI, particularly the ensuing neuronal cell death and cognitive impairments. Tumor necrosis factor-alpha (TNF-aα) is a cytokine that is a master regulator of systemic and neuroinflammatory processes. TNF-aα levels are reported to become rapidly elevated post TBI and, potentially, can lead to secondary neuronal damage. Methods: To elucidate the role of TNF-aα in TBI, particularly as a drug target, the present study evaluated (i) time-dependent TNF-aα levels and (ii) markers of apoptosis and gliosis within the brain and related these to behavioral measures of 'well being' and cognition in a mouse closed head 50 g weight drop mild TBI (mTBI) model in the presence and absence of post-treatment with an experimental TNF-aα synthesis inhibitor, 3,6'-dithiothalidomide. Results: mTBI elevated brain TNF-aα levels, which peaked at 12 h post injury and returned to baseline by 18 h. This was accompanied by a neuronal loss and an increase in astrocyte number (evaluated by neuronal nuclei (NeuN) and glial fibrillary acidic protein (GFAP) immunostaining), as well as an elevation in the apoptotic death marker BH3-interacting domain death agonist (BID) at 72 h. Selective impairments in measures of cognition, evaluated by novel object recognition and passive avoidance paradigms - without changes in well being, were evident at 7 days after injury. A single systemic treatment with the TNF-aα synthesis inhibitor 3,6'-dithiothalidomide 1 h post injury prevented the mTBI-induced TNF-aα elevation and fully ameliorated the neuronal loss (NeuN), elevations in astrocyte number (GFAP) and BID, and cognitive impairments. Cognitive impairments evident at 7 days after injury were prevented by treatment as late as 12 h post mTBI but were not reversed when treatment was delayed until 18 h. Conclusions: These results implicate that TNF-aα in mTBI induced secondary brain damage and indicate that pharmacologically limiting the generation of TNF-aα post mTBI may mitigate such damage, defining a time-dependent window of up to 12 h to achieve this reversal.

AB - Background: The treatment of traumatic brain injury (TBI) represents an unmet medical need, as no effective pharmacological treatment currently exists. The development of such a treatment requires a fundamental understanding of the pathophysiological mechanisms that underpin the sequelae resulting from TBI, particularly the ensuing neuronal cell death and cognitive impairments. Tumor necrosis factor-alpha (TNF-aα) is a cytokine that is a master regulator of systemic and neuroinflammatory processes. TNF-aα levels are reported to become rapidly elevated post TBI and, potentially, can lead to secondary neuronal damage. Methods: To elucidate the role of TNF-aα in TBI, particularly as a drug target, the present study evaluated (i) time-dependent TNF-aα levels and (ii) markers of apoptosis and gliosis within the brain and related these to behavioral measures of 'well being' and cognition in a mouse closed head 50 g weight drop mild TBI (mTBI) model in the presence and absence of post-treatment with an experimental TNF-aα synthesis inhibitor, 3,6'-dithiothalidomide. Results: mTBI elevated brain TNF-aα levels, which peaked at 12 h post injury and returned to baseline by 18 h. This was accompanied by a neuronal loss and an increase in astrocyte number (evaluated by neuronal nuclei (NeuN) and glial fibrillary acidic protein (GFAP) immunostaining), as well as an elevation in the apoptotic death marker BH3-interacting domain death agonist (BID) at 72 h. Selective impairments in measures of cognition, evaluated by novel object recognition and passive avoidance paradigms - without changes in well being, were evident at 7 days after injury. A single systemic treatment with the TNF-aα synthesis inhibitor 3,6'-dithiothalidomide 1 h post injury prevented the mTBI-induced TNF-aα elevation and fully ameliorated the neuronal loss (NeuN), elevations in astrocyte number (GFAP) and BID, and cognitive impairments. Cognitive impairments evident at 7 days after injury were prevented by treatment as late as 12 h post mTBI but were not reversed when treatment was delayed until 18 h. Conclusions: These results implicate that TNF-aα in mTBI induced secondary brain damage and indicate that pharmacologically limiting the generation of TNF-aα post mTBI may mitigate such damage, defining a time-dependent window of up to 12 h to achieve this reversal.

UR - http://www.scopus.com/inward/record.url?scp=84928711417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928711417&partnerID=8YFLogxK

U2 - 10.1186/s12974-015-0237-4

DO - 10.1186/s12974-015-0237-4

M3 - Article

C2 - 25879458

AN - SCOPUS:84928711417

VL - 12

JO - Journal of Neuroinflammation

JF - Journal of Neuroinflammation

SN - 1742-2094

IS - 1

M1 - 45

ER -